KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $495.5 million.

  • Sarepta Therapeutics' Operating Expenses rose 3626.8% to $495.5 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 211.13%. This contributed to the annual value of $1.7 billion for FY2024, which is 1143.08% up from last year.
  • Sarepta Therapeutics' Operating Expenses amounted to $495.5 million in Q2 2025, which was up 3626.8% from $600.0 million recorded in Q1 2025.
  • Sarepta Therapeutics' Operating Expenses' 5-year high stood at $600.0 million during Q1 2025, with a 5-year trough of $223.9 million in Q3 2021.
  • Its 5-year average for Operating Expenses is $384.5 million, with a median of $368.7 million in 2022.
  • Per our database at Business Quant, Sarepta Therapeutics' Operating Expenses crashed by 2033.08% in 2021 and then surged by 6153.74% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Operating Expenses (Quarter) stood at $307.3 million in 2021, then increased by 18.87% to $365.3 million in 2022, then grew by 1.89% to $372.2 million in 2023, then soared by 33.47% to $496.7 million in 2024, then fell by 0.25% to $495.5 million in 2025.
  • Its last three reported values are $495.5 million in Q2 2025, $600.0 million for Q1 2025, and $496.7 million during Q4 2024.